LUMELSERD Trademark

Trademark Overview


On Thursday, July 14, 2022, a trademark application was filed for LUMELSERD with the United States Patent and Trademark Office. The USPTO has given the LUMELSERD trademark a serial number of 97503645. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Monday, June 17, 2024. This trademark is owned by Eli Lilly and Company. The LUMELSERD trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascula...
lumelserd

General Information


Serial Number97503645
Word MarkLUMELSERD
Filing DateThursday, July 14, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateMonday, June 17, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 23, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 4, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, July 18, 2022NEW APPLICATION ENTERED
Thursday, August 4, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, April 12, 2023ASSIGNED TO EXAMINER
Friday, April 14, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 23, 2023PUBLISHED FOR OPPOSITION
Wednesday, May 3, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 23, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 18, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, December 4, 2023SOU TEAS EXTENSION RECEIVED
Monday, December 4, 2023SOU EXTENSION 1 FILED
Monday, December 4, 2023SOU EXTENSION 1 GRANTED
Wednesday, December 6, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 17, 2024SOU TEAS EXTENSION RECEIVED
Monday, June 17, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 17, 2024SOU EXTENSION 2 GRANTED
Monday, June 17, 2024SOU EXTENSION 2 FILED